Enveric Biosciences, Inc. (ENVB)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Enveric Biosciences completes private placement, raising up to $5 million
# 📜 What This Document Is 📰 This document is a highly technical piece of legal paperwork, specifically an exhibit to an 8-K (Current Report) filing. Essentially, it is a **Securities Purchase Agreement**. This agreement governs a large "private placement," which means the company (Enveric Bioscie
March 2026
Enveric Biosciences, Inc. — 8-K Filing
# 🧾 What This Document Is This is a current report on Form 8-K, which companies file with the SEC to announce major events. Attached is a press release (Exhibit 99.1) detailing Enveric's financial results for 2025 and a major corporate update. Think of it as the company's "year-in-review" and "here
SEC filings
All filings →Insider trades
All insider trades →Enveric Biosciences, Inc. has no reported insider trades in the last 90 days.